MedTrace Logo

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

NCT00001381 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-03-04

No results posted yet for this study

Summary

Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

Conditions

  • Bladder Neoplasms
  • Carcinoma, Transitional Cell

Interventions

DRUG

suramin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-03-31
Completion
2000-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00001381 on ClinicalTrials.gov